Ironwood Pharmaceuticals Inc [IRWD] stock is trading at $0.62, up 5.28%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IRWD shares have gain 4.32% over the last week, with a monthly amount drifted -19.94%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] stock has seen the most recent analyst activity on April 15, 2025, when Wells Fargo downgraded its rating to a Equal Weight. Previously, Jefferies downgraded its rating to Hold on April 15, 2025. On April 14, 2025, downgrade downgraded it’s rating to Mkt Perform. Leerink Partners started tracking the stock assigning a Market Perform rating and suggested a price target of $5 on September 09, 2024. CapitalOne downgraded its rating to a Equal Weight and reduced its price target to $4 on August 08, 2024. Craig Hallum started tracking with a Buy rating for this stock on January 17, 2024, and assigned it a price target of $21. In a note dated December 14, 2023, Wells Fargo initiated an Overweight rating and provided a target price of $20 on this stock.
Ironwood Pharmaceuticals Inc [IRWD] stock has fluctuated between $0.53 and $7.11 over the past year. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Ironwood Pharmaceuticals Inc [NASDAQ: IRWD] shares were valued at $0.62 at the most recent close of the market. An investor can expect a potential return of 545.16% based on the average IRWD price forecast.
Analyzing the IRWD fundamentals
Ironwood Pharmaceuticals Inc [NASDAQ:IRWD] reported sales of 317.68M for the trailing twelve months, which represents a drop of -45.05%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.17%, Pretax Profit Margin comes in at 0.08%, and Net Profit Margin reading is -0.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is 0.1 and Total Capital is 0.2. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.79.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5854 points at the first support level, and at 0.5506 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6395, and for the 2nd resistance point, it is at 0.6588.
Ratios To Look Out For
For context, Ironwood Pharmaceuticals Inc’s Current Ratio is 3.34. As well, the Quick Ratio is 3.34, while the Cash Ratio is 2.26. Considering the valuation of this stock, the price to sales ratio is 0.32.
Transactions by insiders
Recent insider trading involved MCCOURT Thomas A, Chief Executive Officer, that happened on May 16 ’25 when 13353.0 shares were sold. Chief Commercial Officer, Gaskins Tammi L completed a deal on May 16 ’25 to sell 2563.0 shares. Meanwhile, Officer MCCOURT Thomas A bought 14661.0 shares on May 19 ’25.
